Table 2.
Reagent | Route of administration (model used) | Reference |
---|---|---|
Naked siRNAs | Intranasal (mouse) | [59] |
Intravaginal (mouse) | [16,42] | |
| ||
Cholesterol-siRNA | Systemic (mouse) | [36] |
Intravaginal (mouse) | [17] | |
| ||
Positively charged protein/Peptide-antibody-siRNA | Systemic (mouse) | [47,48] |
| ||
Aptamer-siRNA | Systemic (mouse) | [66,67] |
| ||
SNALPs | Systemic (cynomolgus monkey) | [37] |
Systemic (mouse) | [84] | |
| ||
Nanoparticles | Intravaginal (mouse) | [35] |
Systemic (mouse) | [85] |
SNALP stable nucleic acid-lipid particles